Theriva Biologics, Inc.
TOVXTheriva Biologics, Inc. (TOVX) is a biotechnology company focused on the development of targeted therapies for cancer and other diseases. The company specializes in the design and engineering of oncolytic viruses and other biologic treatments to improve safety and efficacy in cancer therapy. Based in the United States, Theriva aims to advance innovative solutions through its proprietary platforms and collaborations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 10, 2008 | $0.05 | 2007-12-27 | 2007-12-31 |
Dividends Summary
- Consistent Payer: Theriva Biologics, Inc. has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held TOVX shares during this period received a total of $0.05 per share in dividend income.
- Latest Payout: The most recent dividend of $0.05/share was paid 6588 days ago, on January 10, 2008.
Company News
Theriva Biologics received favorable scientific advice from the European Medicines Agency (EMA) on the design of a Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA approved the proposed trial design, sample size, and adaptive design elements. ...
Theriva Biologics reported unusual trading activity in its stock on October 24, 2025, and stated there are no material undisclosed developments causing the market action. The company is developing cancer therapeutics and has recently presented expanded data from its VIRAGE trial at ESMO 2025.
Theriva Biologics announced positive Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer, with improved overall survival and progression-free survival. The company is preparing for a potential Phase 3 trial and presented retinoblastoma study data at ASCO 2025.
US stock futures are trading higher ahead of a shortened trading session on Christmas Eve. Analysts expect a 'Santa Rally' during this period, which has historically seen positive returns. However, they also caution about potential market corrections in 2025 due to stretched valuations.
Theriva Biologics announced that the FDA provided guidance on the design of a Phase 3 study for their lead candidate VCN-01 in combination with standard chemotherapy for the treatment of metastatic pancreatic cancer. The FDA recommended conducting an independent Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel, rather than expanding the on...
